准核孤儿受体NR4A1:这是肺癌进展和治疗耐药性的关键标
Minhan Jin1,2, Yuhui Wang1, Mingze Song1
1Department of Clinical Laboratory, WeiFang People's Hospital, Shandong Second Medical University, Weifang, China.
Frontiers in oncology
|July 16, 2025
概括
核受体子家族4A组成员1 (NR4A1) 通过各种机制促进肺癌的进展. 向NR4A1为新型肺癌疗法提供了潜力,尽管临床应用需要进一步研究.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 基因规则 基因规则
背景情况:
- 肺癌是导致复杂病原和晚期检测死亡的首要原因.
- 确定新的治疗点对于有效治疗肺癌至关重要.
- 核受体子家族4组A成员1 (NR4A1) 是一种直接的早期基因,与癌症有关.
研究的目的:
- 审查NR4A1在肺癌发展和进展中的多方面的生物学作用.
- 阐明NR4A1在肺癌中调节的分子机制和信号通路.
- 为临床环境中NR4A1向治疗提供理论基础.
主要方法:
- 对肺癌中NR4A1现有研究的文献综述.
- 对NR4A1参与关键癌症特征的分析:扩散,转移,血管新生,免疫逃避,亡和代谢重编程.
- 检查NR4A1与p300/Sp1,AMPK/mTORC1,TGF-β,VEGF-A,PD-1和Bcl-2等信号通路的相互作用.
主要成果:
- NR4A1在肺癌中充当上蛋白,促进细胞增殖,入侵和转移.
- NR4A1影响血管生成,通过T细胞耗尽免疫逃脱,细胞亡调节和代谢重编程.
- 新兴的NR4A1向化合物在临床前研究中表现有前途,但临床验证尚未完成.
结论:
- NR4A1是肺癌中多种瘤性过程的关键调节者.
- 了解NR4A1的机制为开发有针对性的治疗策略提供了基础.
- 需要进一步的研究才能将NR4A1向疗法转化为肺癌的有效临床治疗方法.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.0K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.2K
相关概念视频
Transducer Mechanism: Nuclear Receptors
1.7K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.7K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
The Nucleolus
9.2K
The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
9.2K
lncRNA - Long Non-coding RNAs
9.0K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.0K
